| Methods |
2‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 95‐114 mm Hg on 2 consecutive visits with no more than 8 mm Hg difference in DBP between 2 visits; 8‐week double‐blind treatment |
| Participants |
Eprosartan 600 mg: n=59(40 males,19 females); mean age=54(9) years; baseline sitting SBP=152(12) mm Hg, DBP=100(9) mm Hg;
Eprosartan 1200 mg: n=63(42 males,21 females); mean age=55(10) years; baseline sitting SBP=154(13) mm Hg, DBP=101(9) mm Hg;
Placebo: n=55(39 males,16 females); mean age=54(9) years; baseline sitting SBP=152(20) mm Hg, DBP=100(10) mm Hg |
| Interventions |
Eprosartan 600 mg once daily;
Eprosartan 1200 mg once daily;
Placebo;
taken in the morning |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP;
WDAE |
| Notes |
BP and SE of change reported, endpoint BP and SD not reported; calculated SD of change from N and SE of change; BP data from text, p. 1250; BP measurement device not reported; Jadad score=3; funding source= SmithKline Beecham, Solvay Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
